Clinical Trial Update: A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II dose-escalation and expansion study evaluating BST-236 combined with venetoclax in adults with unfit newly diagnosed acute myeloid leukemia (AML).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BST-236
• Venetoclax (venetoclax)

Snippet

Sponsor: BioSight Ltd. | Conditions: AML, Adult | Phase 1, Phase 2 | Status: UNKNOWN